Speaking before a House Energy and Commerce Committee hearing on the drug, Grassley said repeated requests to talk to an FDA investigator who worked on the Ketek case were rejected. And he says the FDA documents he received were heavily redacted. He says in one case even his own letter requesting documents to the FDA was returned to him with blacked out text.
The FDA has previously said they could not release the documents that Grassley requested due to an ongoing investigation. House Republicans on the committee called the hearing "one sided" noting that FDA officials and representatives from the drug manufacturer were not present. The chairman of the Oversight subcommittee, Congressman Bart Stupak(MI-D) says the committee will hear from FDA and Ketek maker Sanofi-Aventis officials in late March.